Advertisement

Topics

Bavarian Nordic Company Profile

06:04 EDT 25th September 2017 | BioPortfolio

Bavarian Nordic initiated the development of IMVAMUNE® in 1999 and began the first clinical study in 2001. In 2003, Bavarian Nordic was awarded a contract, valued at $29 million, from the U.S. National Institutes of Health (NIH), for the further development of IMVAMUNE®. In 2004, Bavarian Nordic was awarded its second U.S. Government contract, valued at $115 million, to continue advanced development of IMVAMUNE® including clinical trials in individuals with compromised immune systems. In parallel, Bavarian Nordic invested $100 million in the construction of an industrialized manufacturing facility specifically designed to meet the potential demands for IMVAMUNE® by the U.S. Government.


News Articles [144 Associated News Articles listed on BioPortfolio]

Bavarian Nordic A/S: Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE

Sole source request will allow transition toward long-term stockpiling of Bavarian Nordic's smallpox vaccine COPENHAGEN, Denmark, June 16, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today ...

Bavarian Nordic A/S: Bavarian Nordic to Present at Jefferies 2017 Healthcare Conference in New York

COPENHAGEN, Denmark - June 1, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at the...

Bavarian Nordic A/S: Bavarian Nordic to Host First Half 2017 Results Conference Call

COPENHAGEN, Denmark - August 18, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2017 first half results on Friday, August 25, 2017. The management of Bavarian Nordic will hos...

Bavarian Nordic A/S: Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study

COPENHAGEN, Denmark, June 16, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today provided updated guidance for the current anticipated timing of interim and final results from its ongoing PR...

Bavarian Nordic A/S: Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer

Conference call scheduled for 2:00 PM CEST / 8:00 AM EDT tomorrow, Friday, September 15 COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that a...

JJDC buys $33mm in Bavarian Nordic equity

Johnson & Johnson Development Corp. purchased $32.8mm (DKK207.5mm) new Bavarian Nordic AS stock in a private placement of 512,102 shares priced at $64.18. The financing is part of a concurrent deal be...

Janssen and Bavarian Nordic sign $836m deal on Hep B and HIV vaccines

Janssen has signed a new deal with Bavarian Nordic worth up to $836 million to develop target vaccines for hepatitis B and HIV. The projects will combine Bavarian Nordic’s MVA-BN technology with Ja...

Bavarian Nordic A/S: Bavarian Nordic to Host Capital Markets Day in New York City

COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will host a capital markets day for institutional investors and equity analysts on Thursday, September 21, 201...

Drugs and Medications [4 Associated Drugs and Medications listed on BioPortfolio]

Fareston [GTx, Inc.]

These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.FARESTON® (toremifene citrate) 60 mg Tablets oral ...

Comtan [Cardinal Health]

C OMTAN (entacapone) Tablets Rx only Prescribing Information

Comtan [Novartis Pharmaceuticals Corporation]

COMTAN (entacapone) Tablets

Stalevo [Novartis Pharmaceuticals Corporation]

Stalevo® 50 Stalevo® 75 Stalevo® 100 Stalevo® 125 Stalevo® 150 Stalevo® 200 (carbidopa, levodopa and entacapone) Tablets

PubMed Articles [55 Associated PubMed Articles listed on BioPortfolio]

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of met...

Estimating Usual Intake in the 2nd Bavarian Food Consumption Survey: Comparison of the Results Derived by the National Cancer Institute Method and a Basic Individual Means Approach.

The valid estimation of the usual dietary intake remains a challenge till date. We applied the method suggested by the National Cancer Institute (NCI) to data from the 2nd Bavarian Food Consumption Su...

Nordic walking improves trunk stability and gait spatial-temporal characteristics in people with Parkinson disease.

This study aimed to assess the effect of walking with Nordic walking (NW) poles on postural stability and gait spatial-temporal characteristics in individuals with PD and to determine the cognitive lo...

eHealth provides a novel opportunity to exploit the advantages of the Nordic countries in psychiatric genetic research, building on the public health care system, biobanks, and registries.

Nordic countries have played an important role in the recent progress in psychiatric genetics, both with large well-characterized samples and expertise. The Nordic countries have research advantages d...

A rapid LC-MS/MS method for the determination of moniliformin and occurrence of this mycotoxin in maize products from the Bavarian market.

A simple LC-MS/MS method was developed for the determination of moniliformin (MON) in maize and applied for the analysis of samples within the official food surveillance. The homogenized samples were ...

Clinical Trials [41 Associated Clinical Trials listed on BioPortfolio]

Nordic Walking and Chronic Low Back Pain

This is a randimized clinical trial comparing the effect of supervised Nordic walking versus unsupervised Nordic walking versus advice to stay active

Healthy Nordic Foods to Prevent Cardiometabolic Risk in Obese Subjects

This project will examine whether long-term consumption of healthy Nordic foods can maintain a healthy weight also after weight loss, and decrease abdominal fat accumulation and cardiometa...

Eisenmenger Syndrome in the Nordic Countries

This is a historical cohort study with retrospective collection of data comprising all Nordic patient's diagnosed with Eisenmengers syndrome in the period 1977 through 2011. The goal is to...

WS®1442 in Slightly Overweight Subjects

The purpose of this study is to test: 1. Safety of 900 mg or 1800 mg of WS® 1442 per day in overweight subjects (BMI 25 to 29,9 kg/m²) 2. Pharmacodynamic effect of WS® ...

Nordic Hamstring and Repeated-sprint Ability in Football (Soccer) Players

The purpose of the study is to investigate the efficacy of a 10-week intervention, using the Nordic Hamstring exercise, on repeated-sprint ability in male sub-elite football players. The p...

Companies [45 Associated Companies listed on BioPortfolio]

Bavarian Nordic

Bavarian Nordic initiated the development of IMVAMUNE® in 1999 and began the first clinical study in 2001. In 2003, Bavarian Nordic was awarded a contract, valued at $29 million, from the U.S. Natio...

Bavarian Nordic Research Institute A/S

Bavarian Nordic is a commercially viable international biopharmaceutical company through:Biopharmaceutical innovations Novel prophylactic and therapeutic approaches Development, production, testing an...

Bavarian Nordic A/S

In 2004 we marked our 10 year anniversary as a company. Over the past decade we have developed the early MVA vector research into a broad commercial vaccine vector technology.

Alliance for Biosecurity

The Alliance for Biosecurity was formed in June of 2005 by biopharmaceutical companies and the Center for Biosecurity of the University of Pittsburgh Medical Center. Alliance members are committed to...

Nordic Nanovector

Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel inno...

More Information about "Bavarian Nordic" on BioPortfolio

We have published hundreds of Bavarian Nordic news stories on BioPortfolio along with dozens of Bavarian Nordic Clinical Trials and PubMed Articles about Bavarian Nordic for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bavarian Nordic Companies in our database. You can also find out about relevant Bavarian Nordic Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record